Table 1.

Effect of docetaxel on splenic cell populations

CellsTreatmentPretreatmentTime posttreatment
Day 1Day 2Day 3Day 4Day 7
SplenocytesPBS1.1 × 1081.4 × 1081.1 × 1081.1 × 1089.6 × 1071.1 × 108
Docetaxel8.1 × 1077.4 × 1078.6 × 1071.1 × 1081.1 × 108
CD4+PBS18%2.0 × 10717%2.4 × 10718%2.0 × 10717%1.9 × 10715%1.4 × 10725%2.8 × 107
Docetaxel19%1.5 × 10719%1.4 × 10719%1.6 × 10710%1.1 × 10719%2.1 × 107
CD8+PBS13%1.4 × 10711%1.5 × 1078%8.8 × 10610%1.1 × 1069%8.6 × 10614%1.5 × 107
Docetaxel13%1.0 × 10714%1.0 × 10712%1.0 × 1077%7.7 × 10613%1.4 × 107
CD19+PBS60%6.6 × 10762%8.7 × 10764%7.0 × 10758%6.4 × 10752%5.0 × 10761%6.7 × 107
Docetaxel54%4.4 × 10758%4.3 × 10752%4.5 × 10740%4.4 × 10749%5.4 × 107
DX5+PBS2.8%3.1 × 1062.7%3.7 × 1062.4%2.6 × 1062.5%2.8 × 1062.0%1.9 × 1063.4%3.7 × 106
Docetaxel2.7%2.2 × 1062.5%1.8 × 1062.2%1.9 × 1061.8%2.0 × 1064.4%4.8 × 106
TregsPBS5%5.5 × 1064.0%5.6 × 1068.8%9.7 × 1067.2%7.9 × 1068.1%7.8 × 1067.3%8.0 × 106
Docetaxel6.7%5.4 × 10611.5%8.5 × 1069.5%8.2 × 1069.2%1.0 × 1078.5%9.4 × 106
  • NOTE: C57BL/6 mice (n = 5 per group) were given 0.5 mg docetaxel i.p. on days −4, −2, and 0. Control mice received PBS only. Mice were sacrificed 1, 2, 3, 4, and 7 d posttreatment. After lysis of RBC, splenocytes were counted and stained for T cells (CD3+, CD4+, CD8+), B cells (CD19+), natural killer cells (DX5+), and Tregs (CD4+CD25+FoxP3+). Of the CD4+cells that expressed CD25, >98% also stained positive for FoxP3. Cells were analyzed by flow cytometry. Percentages denote the percent of splenocytes. Bold numbers indicate a significant difference (P < 0.05) in docetaxel versus PBS treated mice. This experiment was repeated twice.